Study of Nimotuzumab Combined With IMRT in Elder Patients With Cervical Squamous Cell Carcinoma
To evaluate the efficacy and safety of Nimotuzumab combined with IMRT in elder patients with locally advanced cervical squamous cell carcinoma
Cervical Squamous Cell Carcinoma
DRUG: Nimotuzumab|RADIATION: EBRT combined with brachytherapy
3-year disease-free survival(DFS), The rate of patient without disease in 3 years after treatment, up to 3 years
Complete response rate(CRR), The percentage of subjects who achieve complete response by imaging assessment from the end of the treatment to disease progression, 3 months later after treatment|Objective response rate(ORR), The percentage of patients who experienced complete or partial cancer shrinkage or disappearance after treatment, 3 months later treatment|3-year overall survival(OS), The rate of patient alive in 3 years after treatment, up to 3 years|The change of tumor related markers, the correlation of the value of SCCï¼ŒCyfra 21-1 and therapeutic effect \[The changes of serum tumor markers (such as SCC-Ag and CYFRA21-1) were observed before and after treatment\], up to 3 years|The change of cervical tumor, the change of the volume of the cervical tumor at diagnosis and before brachytherapy, At diagnosis and before brachytherapy|QUALITY OF LIFE(QoL), Quality of life assessed by EORTC QLQ-CX 24 \[EORTC QLQ-CX 24 is a specific quality of life assessment scale based on EORTC QLQ-C 30, with 24 items\], up to 3 years|SAFETY, Including severity of adverse events, the incidence of adverse events and serious adverse events. Adverse events should be reported and graded according to CTCAE version 5.0, up to 3 years
This is a perspective, multi-center, open-label and single arm study.